Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00708175 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

A Phase 4 study of Bone Metabolism, sponsored by Takeda.

Completed
Registry status
Phase 4
Development phase
156
Enrollment target
20
Study locations

NCT00708175: Completed Phase 4 study of Bone Metabolism, sponsored by Takeda.

NCT00708175 is a Phase 4 study of Bone Metabolism that has completed, run by Takeda. The registered enrollment target is 156 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00708175, a Phase 4 study of Bone Metabolism, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 4
Development phase
156 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.

Primary Outcome

The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray.

Conditions Studied

Bone Metabolism

Interventions

  • DRUG Placebo
  • DRUG Pioglitazone

Study Locations (20)

California

  • - Greenbrae
  • - Los Banos
  • - San Diego
  • - Walnut Creek
  • - West Hills

Florida

  • - Boynton Beach
  • - Hialeah
  • - Jupiter

Colorado

  • - Lakewood
  • - Longmont

Georgia

  • - Dunwoody
  • - Gainesville

Iowa

  • - Des Moines
  • - Iowa City

Hawaii

  • - Honolulu

Idaho

  • - Idaho Falls

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2008-05
Est. Completion 2011-02
Phase Phase 4
Takeda

408 total trials

What the finished NCT00708175 record still lists

NCT00708175 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (70% lower).

The record links to 1 condition, with Bone Metabolism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00708175 names 20 study sites across 11 states, led by California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT00708175 about?

NCT00708175 is a clinical study titled "Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.". The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.

What is the current status of trial NCT00708175?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 156 participants. The study started on 2008-05. Estimated completion is 2011-02.

What conditions does trial NCT00708175 study?

This clinical trial studies the following conditions: Bone Metabolism.

What interventions are being tested in trial NCT00708175?

The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT00708175?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00708175 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00708175's enrollment target sits among peer trials

156 521st of 2000 higher than 1,476 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03082755 · 156 participants · Phase 4

    Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

  • NCT04047628 · 156 participants · Phase 3

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

  • NCT04166877 · 156 participants · Phase 4

    Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

  • NCT04533464 · 156 participants · Phase 2

    MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00708175, the US trial registry maintained by the National Library of Medicine. NCT00708175 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.